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Estrogenic Modulation of Uropathogenic Escherichia coli Infection
Pathogenesis in a Murine Menopause Model
Caihong Wang,a Jane W. Symington,a Emily Ma,a Bin Cao,a Indira U. Mysorekara,b
Departments of Obstetrics and Gynecologya and of Pathology and Immunology,b Washington University School of Medicine, St. Louis, Missouri, USA
Recurrent urinary tract infections (UTIs), primarily caused by uropathogenic Escherichia coli (UPEC), annually affect over 13
million patients in the United States. Menopausal women are disproportionally susceptible, suggesting estrogen deficiency is a
significant risk factor for chronic and recurrent UTI. How estrogen status governs susceptibility to UTIs remains unknown, and
whether hormone therapy protects against UTIs remains controversial. Here, we used a mouse model of surgical menopause by
ovariectomy and demonstrate a protective role for estrogen in UTI pathogenesis. We found that ovariectomized mice had signif-
icantly higher bacteriuria, a more robust inflammatory response, and increased production of the proinflammatory cytokine
interleukin-6 (IL-6) upon UPEC infection compared to sham-operated controls. We further show that response of the urothelial
stem cell niche to infection, normally activated to restore homeostasis after infection, was aberrant in ovariectomized mice with
defective superficial urothelial cell differentiation. Finally, UPEC-infected ovariectomized mice showed a significant increase in
quiescent intracellular bacterial reservoirs, which reside in the urothelium and can seed recurrent infections. Importantly, this
and other ovariectomy-induced outcomes of UTI were reversible upon estrogen supplementation. Together, our findings estab-
lish ovariectomized mice as a model for UTIs in menopausal women and pinpoint specific events during course of infection that
are most susceptible to estrogen deficiency. These findings have profound implications for the understanding of the role of estro-
gen and estrogen therapy in bladder health and pathogen defense mechanisms and open the door for prophylaxis for meno-
pausal women with recurrent UTIs.
Urinary tract infections (UTIs), primarily caused by uropatho-genic Escherichia coli (UPEC), are among the most common
frequently recurring infectious diseases in humans (1). Meno-
pausal women, who have greatly reduced levels of the sex hor-
mone estrogen, are more likely to have recurrent/chronic UTIs
than any other group (2–5); 53% of menopausal women with a
UTI will have at least one recurrence (6). Consistent with evidence
from animal and human studies, demonstrating that sex hor-
mones have an important effect on the female lower urinary tract
during adult life, estrogen receptors have been identified in the
bladder, urethra, and pelvic floor. In addition, fluctuations in the
circulating levels of estrogen during the menstrual cycle and in
pregnancy influence the prevalence of urinary symptoms. Fur-
thermore, decreased estrogen during menopause is a significant
risk factor for UTIs (3, 7–9) and bladder barrier dysfunction (10),
but little is known about the mechanisms underlying this in-
creased susceptibility.
A murine model of UTI shows that UPEC infection of the
urinary bladder follows a multistep pathogenic cycle: UPEC in-
vades superficial urothelial cells by binding cell surface uroplakin
receptors (11). During the acute stage of infection (0 to 72 h),
intracellular UPEC replicates rapidly and establishes cytoplasmic
biofilms termed intracellular bacterial communities (IBCs),
which are also observed in humans (12, 13). The host response
includes induction of proinflammatory cytokines, including in-
terleukin 6 (IL-6), exfoliation of the superficial urothelial cells
containing IBCs into the urine, and influx of innate immune cells,
particularly neutrophils. This rapid proinflammatory response
aids in defending against pathogens (14, 15). The damaged epi-
thelial barriers are restored by urothelial stem cell niche activation
and terminal differentiation of superficial cells (16). Despite the
host defense response, however, a subset of UPEC can survive and
establish long-term reservoirs, likely within autophagosomal
compartments, in urothelial cells (17, 18). These reservoirs,
termed quiescent intracellular reservoirs (QIRs), can serve as
seeds for recurrent infection (19).
Estrogen has been used widely to treat urinary symptoms in
postmenopausal women, but the evidence from randomized stud-
ies does not consistently show that estrogen therapy is effective in
reducing recurrence of UTIs (20–28). These inconsistencies may
be because the trials used variable dosages and durations of treat-
ment. Given that the causes of UTIs are complex and multifacto-
rial, gaining a clear understanding of the role of estrogen in UPEC
pathogenesis requires development of an animal model with a
defined genetic background in which estrogen levels can be ma-
nipulated in a controlled manner. However, there have been lim-
ited studies using animal models to examine the estrogenic mod-
ulation of UTI progression. One study has suggested that
supplementation of 17-estradiol increased the susceptibility of
ascending UTI in the kidneys, but not in the bladder (22). Thus,
the dynamic interaction between estrogen signaling and UPEC
pathogenesis in the urothelium still remains to be elucidated. In
this report, we employ a murine model of surgical menopause,
ovariectomy, to directly test the hypothesis that changes in hor-
mone levels play a role in regulating the course of UTIs in the
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bladder and present evidence that estrogenic deficiency adversely
affects the course of UPEC pathogenesis, in particular UPEC per-
sistence in the bladder wall and the urothelial regenerative re-
sponse upon infection.
MATERIALS AND METHODS
Mice. All protocols were approved by the animal studies committee of the
Washington University School of Medicine (Animal Welfare Assurance
number A-3381-01). Mice were maintained under pathogen-free condi-
tions in a barrier facility under a strict 12-h light/dark cycle.
Ovariectomy. Seven- to 8-week-old C57BL/6 female mice (NCI
Mouse Repository, Frederick, MD) were anesthetized and the ovaries ex-
cised as described previously (29). For sham surgery, the same procedures
were performed without removal of the ovaries. The animals were allowed
at least 2 weeks to recover.
17-estradiol supplementation. A 90-day time-release pellet con-
taining 0.01 mg of 17-estradiol (Innovative Research of America, Sara-
sota, FL) was implanted under the side of the neck of each animal. The
mice were maintained on the pellets for 60 to 90 days until sacrifice.
Inoculations of mice. UTI89 (19), a pathogenic UPEC strain, was
grown statically in Luria-Bertani (LB) broth for 17 h at 37°C. Mice were
anesthetized and inoculated, via transurethral catheterization, with 50 l
of a bacterial suspension (107 CFU) of UTI89 in phosphate-buffered sa-
line (PBS) as described previously (11, 13).
Tissue histopathology and inflammation scoring. Bladders were
processed as described previously (17). Briefly, bladders were aseptically
removed immediately after sacrifice, fixed in methacarn (60% methanol,
30% chloroform, and 10% acetic acid), and embedded in paraffin. Five-
micrometer-thick tissue sections were stained with hematoxylin and eo-
sin. Inflammation scores of infected bladders were determined as de-
scribed previously (30).
Histochemical and immunofluorescence analysis. Bladders were
processed as described above. The following primary antibodies were used
on bladder tissue sections: rabbit polyclonal antibody (pAb) to E. coli
(1:500; United States Biological, Swampscott, MA), mouse monoclonal
antibody (MAb) to Uroplakin III (1:100; Fitzgerald, Acton, MA), goat
pAb to BrdU (31), rat MAb to Lamp1 (1:50, clone ID4B; Developmental
Studies Hybridoma Bank, Iowa City, IA), rabbit pAb to p27kip1 (1:500;
Sigma, St. Louis, MO), rabbit pAb to cytokeratin 5 (CK5) (1:500; Abcam,
Cambridge, MA), and mouse MAb to E-cadherin (1:500, BD Transduc-
tion Labs, San Jose, CA). After three 5-min PBS washes at room temper-
ature, antigen-antibody complexes were detected with species-specific Al-
exa Fluor 488-, Alexa Fluor 594-, or Alexa Fluor 647-conjugated
secondary antibodies (1:500; Invitrogen, Carlsbad, CA). Images were ob-
tained using a Zeiss Apotome microscope.
QIR quantification. Six separate 5-m serial sections over a thickness
of 300 m were immunostained with antibodies against E. coli, Lamp1,
and E-cadherin (listed above) and imaged at 63. The total number of
Lamp1-positive UPEC reservoirs in the six sections was counted and re-
ported as the number of QIRs per bladder (n 18 to 23 mice per group).
BrdU labeling. BrdU labeling was performed as described previously
(16).
Urinalysis and bacterial titers. Urine specimens from infected mice
were collected at 0 to 14 days postinfection (dpi) and serially diluted in
PBS; 5l of each dilution was spotted onto LB plates six times as described
previously (11). Bacterial titers were calculated as CFU/ml of urine. Urine
sediments were obtained by cyto-centrifuging 50l of a 1:5 dilution of the
urine onto poly-L-lysine-coated glass slides, which were then stained for
inflammatory scoring as described previously (30).
Bioplex cytokine bead array assay. Sera were obtained at 6 h postin-
fection (hpi), and cytokine levels were measured using the Bioplex kit
from Bio-Rad (Bio-Rad, Hercules, CA) as described previously (17, 32).
Quantitative real-time PCR (qRT-PCR) analysis. Bladders from
sham-operated controls (SHAM) or ovariectomized (OVX) mice (3 mice
per group) were removed at 6 hpi. RNA was isolated from the bladders
using TRIzol (Invitrogen, Carlsbad, CA) and treated with DNase I (Am-
bion, Austin, TX) to remove contaminating DNA. cDNAs were synthe-
sized from 2 g of total RNA using Superscript II RNase H reverse trans-
criptase (Invitrogen, Carlsbad, CA). Expression of Bmp4 and p27kip1 was
detected by real-time PCR using an ABI Prism 7700 sequence detection
system and SYBR green PCR master mix (Applied Biosystems, Foster
City, CA). Expression of each target was measured in triplicate. Relative
quantification was determined by using the comparative threshold cycle
(CT) method with 18S expression as a control, as described in the ABI
Prism 7700 sequence detection system user bulletin. The following prim-
ers were used for real-time PCR: 18S (5=-CGGCTACCACATCCAAGGA
A-3= and 5=-GCTGGAATTACCGCGGCT-3=), Bmp4 (5=-CAACACCAT
GATTCCTGGTAACC-3= and 5=-TCCCGGTCTCAGGTATCAAACT-
3=), and p27kip1 (5=-CGGCGGCAAGGTTTGGAGAGG-3= and 5=GGAG
GAGGCAGGAGGAGGTGG-3=).
Statistical analysis. Two-sample unpaired t tests, nonparametric
Mann-Whitney U tests, and one-way analyses of variance (ANOVA) fol-
lowed by a Tukey’s multiple-comparison posttest were performed using
GraphPad Prism software. In cases where nwas5, a Shapiro-Francia test
was performed for normality. A t test was performed if the normality
test was not significant. A Mann-Whitney U test was used if the normality
test was significant or n was 5. For time course studies, the standard
error (SE) used in the t test was estimated by ANOVA, and two-sample
tests were performed at individual time points. To control for false posi-
tives, Bonferroni-adjusted P values at individual time points are reported.
A P value of0.05 was used as the cutoff for statistical significance.
RESULTS
Ovariectomized mice exhibit delayed bacterial clearance from
the bladder. To determine whether removal of ovaries affects the
UPEC pathogenic cycle, we generated ovariectomized (OVX)
mice, which exhibited reduced estrogen levels, and sham-oper-
ated controls (SHAM). We then infected the bladders of adult
OVX and SHAM mice with UPEC and monitored the progress of
the UTI by measuring the shedding of bacteria into the urine
(bacteriuria) for 2 weeks (schema in Fig. 1). We found that OVX
mice exhibited significantly higher and more sustained bacteri-
uria, evidenced by higher bacterial load at three to 10 days postin-
fection (dpi), than SHAM mice, who cleared the infection by day
3 (Fig. 2A). This finding indicates that removal of ovaries results in
a prolonged UTI.
Ovariectomy decreases exfoliation of superficial urothelial
cells. One of the first host responses to UPEC infection in the
bladder is exfoliation of the superficial urothelial cells containing
IBCs into the urine. Although the majority of superficial cells were
sloughed into the urine in SHAM mice at 24 h postinfection (hpi)
FIG 1 Experimental design: diagram illustrating experimental strategy.
Wang et al.
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(Fig. 2B), a relatively unperturbed superficial layer was evident in
OVX mice (arrow in Fig. 2C; note the thickness of the superficial
cell layer marked by expression of uroplakin III [UPIII]). Addi-
tionally, UPEC staining of the bladders indicated that more IBCs
remained in the intact superficial cells in OVX mice (arrowheads
in Fig. 2E) than in SHAM mice (Fig. 2D) at this time point. Thus,
ovary removal resulted in decreased exfoliation of infected super-
ficial cells at the acute stage (24 hpi), which might contribute to
the prolonged UPEC infection.
Estrogen-deficient mice display a severe proinflammatory
response upon UPEC infection. In addition to the sloughing of
superficial cells, the host responds to the pathogen by inducing
proinflammatory cytokines, including IL-6 (33), and recruiting
immune cells, such as neutrophils, to the infected site. Cytological
analysis of urine samples of infected mice revealed greater extent
of neutrophil infiltration in the urine at 24 and 72 hpi in OVX
mice than in SHAM mice (Fig. 3A). Next, we performed cytokine
assays using Bioplex bead arrays on sera to determine whether
increased influx of neutrophils was associated with high produc-
tion of cytokines in OVX mice. We observed significantly higher
levels of IL-6 in sera from infected OVX mice than from SHAM
mice at 6 hpi (Fig. 3B), suggesting an overall enhanced systemic
and luminal proinflammatory response to infection in OVX mice.
To determine whether bladder tissue of OVX mice was prone
to greater inflammation, we examined bladders from SHAM and
OVX mice at 24 hpi and quantified the level of tissue inflamma-
tion. We found that bladders from UPEC-infected OVX mice ex-
hibited higher inflammation scores than SHAM mice (Fig. 3C).
Histopathological analyses revealed more severely inflamed blad-
der tissue in OVX mice with greater immune/inflammatory influx
including neutrophils (arrow in Fig. 3E) and severe edema (ar-
rowhead in Fig. 3E) than bladders from SHAM mice (Fig. 3D).
Together, these results suggest that OVX mice mount a more ro-
bust and prolonged proinflammatory response to UPEC infection
than SHAM mice.
Ovariectomization affects USC niche response to UPEC in-
fection. Superficial urothelial cell loss and associated inflamma-
tion induced by UPEC infection cause damage to urothelial bar-
riers that are critical for bladder function. To restore homeostasis,
the urothelium activates a regeneration response fueled by activa-
tion of the urothelial stem cell (USC) niche and proliferation of
the basal urothelial layer. Niche activation and terminal differen-
tiation into mature superficial urothelial cells is dependent on the
Bmp4 signaling pathway (16, 34). We sought to determine
whether estrogen deficiency affected the USC response to infec-
tion. Because the predominant estrogen receptor in the bladder,
ER, is mainly expressed in the basal USC layer (35), we specu-
lated that the basal USC layer is most likely to be affected by es-
trogen deficiency. We found that OVX mice exhibited a thickened
CK5 (a marker for basal cells) (16) cell layer at 14 dpi than
SHAM mice and, correspondingly, a thinner UPIII superficial
cell layer (Fig. 4A and B).
The thickened basal cell layer in OVX mice could be a result of
increased and sustained USC proliferation or a defect in terminal
differentiation. To determine whether there was a block in termi-
nal differentiation, we assessed expression of Bmp4 pathway com-
ponents. qPCR analysis revealed that expression of Bmp4 and its
downstream target p27kip1 were both downregulated in OVX
mice after UPEC infection (Fig. 4D and E). We also found that
bladders from OVX mice had fewer p27kip1-positive nuclei than
SHAM mice (Fig. 4C and F), suggesting that these cells were not
exiting the cell cycle to terminally differentiate. We assessed pro-
liferation by BrdU labeling and found no significant differences in
proliferative activity between SHAM and OVX mice (Fig. 4G),
indicating that the thickened basal cell layer in OVX mice was not
due to increased proliferation. Together, our findings suggest that
the Bmp4 pathway was downregulated, and the differentiation of
basal cells to superficial cells was blocked by ovariectomy, thus
impairing the USC niche adaptation to infection.
Estrogen deficiency enhances UPEC persistence. Even after
epithelial exfoliation and proinflammatory responses eliminate
the majority of intracellular bacteria, a subset of UPEC can survive
and establish long-term reservoirs, termed quiescent intracellular
reservoirs (QIRs), which serve as seeds for recurrent infection
(19). We thus examined SHAM and OVX bladders at 14 dpi to
determine whether enhanced bacterial colonization in the blad-
ders of OVX mice at the acute stage of infection was associated
with increased establishment of QIRs. Because UPEC can estab-
lish reservoirs containing small numbers of bacteria that are below
the detectable limit in bladder titers (19), we investigated QIR
formation by immunostaining bladder sections with antibodies to
UPEC and Lamp-1, a marker for the vesicles in which QIRs are
found (17, 19) (Fig. 4H). Bladders of OVX mice harbored signif-
FIG 2 Ovariectomized mice exhibit prolonged infection. (A) CFU counts of
bacteriuria over a time course in SHAM, OVX, and OVXE2 mice plotted as
means  standard errors of the means (SEM) of the log10 value (n  6 to 12
mice/time point/group in two experiments). *, P 0.05 (between SHAM and
OVX mice by two-way ANOVA with a Bonferroni posttest). (B to E) Immu-
nofluorescence (IF) analysis reveals more UPIII (red) superficial cells in OVX
mice than SHAM mice at 24 hpi (B and C), as well as more intracellular UPEC
communities (green) (D and E). Bar 20 m.
Estrogen and Pathogenesis of UTIs
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icantly more QIRs in Lamp1-positive vesicles than bladders of
SHAM mice (Fig. 4I). Thus, estrogen deficiency is associated with
increased establishment of persistent bacterial reservoirs.
Estrogen replacement therapy overall restores bladder re-
sponse to UPEC to premenopausal state. Ovariectomy results in
decreases in both estrogen and progesterone levels. Thus, to estab-
lish whether the effects of OVX we observed were mediated exclu-
sively by estrogen, we supplemented a cohort of OVX mice with
17-estradiol (OVXE2) for 8 weeks before induction of a UTI
and followed the pathogenic cycle as described above. Exogenous
administration of E2 did not significantly affect the bacterial loads
in the urine (Fig. 2A). We next asked whether the immunological
responses of the OVX mice to infection were rescued by estrogen
supplementation. We observed a slight, but not significant, de-
crease in neutrophil infiltration in the urine at 24 and 72 h after
UPEC infection (Fig. 3A). However, we observed significantly
lower IL-6 serum levels (Fig. 3B) and low inflammation levels in
the bladder mucosa (Fig. 3C; compare panel F to E) in OVXE2
mice than OVX mice. Additionally, we did not observe a thicken-
ing of the CK5 basal cell layer in OVXE2 mice (Fig. 4A). To-
gether, these findings suggest that the increased and sustained
inflammation and tissue damage observed in OVX mice is, at least
in part, due to estrogen deficiency. Finally, we asked whether es-
trogen supplementation could reduce the number of latent QIRs
that formed in OVX mice. We found that bladders from OVX
mice that received E2 supplementation contained fewer QIRs than
mice that were ovariectomized but did not receive E2 supplemen-
tation (Fig. 4I). In fact, at 14 dpi, OVX mice receiving E2 before
infection harbored similar numbers of QIRs as SHAM mice, indi-
cating that the enhanced QIR formation we observed in OVX mice
was largely due to estrogen deficiency.
DISCUSSION
Here, we employ a murine model of surgical menopause by ovari-
ectomy to demonstrate that estrogen plays a protective role in
regulating the host response to UPEC infection. We show that
ovariectomization results in prolonged and more severe infection
that is associated not only with increased and sustained bacteriuria
but also with elevated inflammation and a significantly greater
number of persistent bacterial reservoirs. We further demonstrate
that estrogen deficiency is associated with an aberrant tissue re-
generative response wherein restoration of urothelial barriers is
delayed considerably. Thus, our model has shown that critical
aspects of disease pathogenesis are under estrogenic control;
namely, tissue restoration and regeneration following infection-
induced injury, inflammatory response to UPEC, and, impor-
tantly, UPEC persistence in the bladder wall. We propose that our
model lays the groundwork for exploring the mechanisms of es-
trogenic action and for testing hormone therapy efficacy.
Estrogen and immune response. High estrogen levels have
potent anti-inflammatory functions, including repression of pro-
inflammatory gene transcription and cytokine production such as
IL-6 (36–39). The anti-inflammatory effects of estrogens have
been observed in several disease models, including autoimmunity,
atherosclerosis, arthritis, inflammatory bowel disease, asthma,
and influenza (40–42). Our data are consistent with an inhibitory
role of estrogen on IL-6 production (38, 43) and the presence of
systemic elevated IL-6 levels in menopausal women (39). A
heightened IL-6 response may play a role in the pathogenesis of
UTIs in menopausal patients similar to other chronic inflamma-
tory diseases such as rheumatoid arthritis (39). Our data suggest
that estrogen might contribute to the functional integrity of the
FIG3 Ovariectomized mice display a severe proinflammatory response upon UPEC infection. (A) Urine inflammation scores are higher in UPEC-infected OVX
mice than SHAM mice at 24 and 72 hpi. *, P 0.05 (by Mann-Whitney U test). (B) Bioplex cytokine assay of sera reveals more IL-6 secreted in UPEC-infected
OVX mice than SHAM mice at 6 hpi, reversible upon E2 supplementation. *, P  0.05; **, P  0.01 (by one-way ANOVA followed by Tukey’s multiple-
comparison posttest). (C) Inflammation scoring of bladder tissue at 24 hpi reveals higher scores in OVX mice than SHAM mice, reversible upon E2 supplemen-
tation. *, P 0.05 (by Mann-Whitney U test). (D to F) Hematoxylin and eosin staining of bladders from SHAM, OVX, and OVXE2 mice at 24 hpi depicts
greatest inflammation (arrow points to neutrophils) and edema (arrowhead) in OVX mice. Bar 40 m.
Wang et al.
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FIG 4 Estrogen deficiency leads to aberrant urothelial regeneration and increased bacterial reservoir formation. (A) CK5 and UPIII staining of bladders at 14 dpi
depicting thickened CK (green) cell layer in the OVX urothelium. (B) IF analysis depicts reduced UPIII (red) staining in OVX bladders at 14 dpi. Dotted lines
demarcate epithelium from bladder stroma. Bar 20m. (C) p27kip1 staining of bladders at 14 dpi indicates fewer p27kip1 cells in OVX urothelia. Bar 40
m. (D and E) qRT-PCR analysis reveals Bmp4 (D) and p27kip1 (E) gene expression is downregulated upon UPEC infection at 6 hpi in OVX mice. (F)
Quantification of p27kip1 nuclei reveals reduced numbers in OVX bladders at 14 dpi. Bars represent means SEM. *, P 0.05 (by unpaired two-tailed t test).
(G) BrdU counts at the indicated times after infection (n 3 to 6 mice/time point/condition). Bars represent means SEM. (H) Representative image depicting
a quiescent intracellular reservoir (QIR). Bar 10m. (I) Quantification of QIRs in bladders at 14 dpi reveals a highly significant increased number in OVX mice,
reversible upon E2 supplementation (n 6 sections/bladder, 10 to 15 mice/group; n 3 experiments). *, P 0.05; **, P 0.01 (by one-way ANOVA followed
by Tukey’s multiple-comparison posttest).
Estrogen and Pathogenesis of UTIs
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bladder barrier by quenching the inflammatory response associ-
ated with UTI. Excessive IL-6 or production of other proinflam-
matory cytokines can result in urothelial damage that may affect
disease outcome. It has been previously shown that elevated and
sustained levels of serum cytokines, including IL-6, along with
IL-5, granulocyte colony-stimulating factor (G-CSF), and kerati-
nocyte-derived chemokine (KC) (biomarkers of local and sys-
temic acute inflammation), precede the development of chronic
cystitis and that the early immune events serve as a “checkpoint”
for predicting infection outcomes (32). The elevated early IL-6
response in OVX mice may predispose the mice to the prolonged
high-titer UPEC urine load noted. This window of time may be
the key in setting the stage for disease outcome and/or UTI recur-
rence. Our data, together with other studies in postmenopausal
women (44), suggest that IL-6 levels may be a major biomarker of
chronic inflammatory activity in a postmenopausal state.
Estrogen, urothelial stemcell niche activation, and recurrent
UTIs. UPEC can persist indefinitely as quiescent reservoirs within
the immature basal cells of the bladder and can reemerge to seed
recurrent UTIs (19). The basal cells are the early progenitor cells
and serve as a protective niche in which UPEC can escape immune
detection and evade exfoliation. Here, we showed that hypoestro-
genization induces a thickened basal cell layer due to the disrupted
differentiation process of basal cells to superficial cells. OVX mice
not only displayed low estrogen levels, but the expression of Bmp4
and its downstream target p27kip1 were downregulated in these
mice. Because the Bmp4 pathway is required for USC niche acti-
vation and differentiation (16), this result may explain why the
basal cell layer was thicker in OVX mice than in SHAM mice after
UPEC infection. The mechanisms by which Bmp4 signaling is
modulated by estrogen in response to UPEC infection in the blad-
der are unclear, but one possibility is that Bmp4 signaling may be
modulated by the glycosaminoglycan (GAG) layer covering the
urothelium. GAGs are large linear polysaccharides with a high
degree of structural heterogeneity mediated by GAG biosynthetic
enzymes (45). GAGs are known to modulate growth factors (46–
48). We have previously shown that levels of a GAG-sulfating
enzyme, HS6ST1, a key modulator of Bmp4 signaling, are in-
creased upon infection (49). Additionally, we have shown that
estrogen plays a key role in influencing the GAG thickness and the
increased expression of GAG sulfation enzymes over the course of
UPEC infection (29). Together, this leads us to speculate that in-
creased sulfation of GAGs may modulate the downregulation of
Bmp4 signaling and thereby the USC niche response to infection.
UTI recurrence may depend on UPEC’s ability to manipulate
differentiation and proliferation of USCs. Thus, the thickened
USC layer may provide more protective niches for QIRs to form.
These QIRs may hide in the bladder longer due to the slower
turnover rate from basal cells to superficial cells. Traditional anti-
biotic therapies are not effective against bacteria sequestered in
QIRs and can also increase the risk of driving the pathogens into
quiescence (50). As these reservoirs are a source of recurrent UTIs,
any reduction in their establishment and greater understanding of
the interplay between latency and estrogen signaling will have
great significance for studying infectious disease in aging female
populations.
Estrogen therapy andUTIs. Our results suggest that hormone
therapy is beneficial to OVX mice with UTI, and this beneficial
effect may be due to the downregulation of the proinflammatory
response and the homeostasis of urothelium promoted by the
presence of exogenous estrogen. While further studies using mul-
tiple UPEC strains would be valuable, we propose that our find-
ings provide an explanation for why menopausal women may be
at greater risk for recurrent UTIs. In postmenopausal women,
efficacy of estrogen supplementation in UTI prevention has relied
upon alterations in bacteriuria loads as a measure of success. Our
findings showing that estrogen supplementation does not affect
bacteriuria may offer an explanation for the contradictory reports
and are consistent with those of Curran and coworkers, who did
not observe changes in bacterial load in the bladder (22), as well as
another study demonstrating that estrogen’s effect on disease out-
come was independent of influenza viral load (40). Although test-
ing different levels of E2 supplementation and the short-term and
long-term consequences of therapy remain to be determined, our
work suggests that estrogen therapy may be beneficial to women
with recurrent UTIs and could have implications for reducing the
burden of this infectious disease in aging populations. For exam-
ple, longer-term estrogen therapy with transiently increased doses
during an acute episode of UTI might be beneficial. Our data may
have significant clinical implications for understanding the etiol-
ogy of recurrent UTIs in menopausal women and warrant further
studies for potential usage of estrogen as a therapeutic interven-
tion.
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